Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (May 2022)
20 slides from Recce Pharmaceuticals's investor presentation, May 16, 2022
Slide 1: Biotech Investors Luncheon – Emerging Biotech Conquering Global Markets
ASX Announcement Biotech Investors Luncheon – Emerging Biotech Conquering Global Markets SYDNEY Australia, 16 May 2022: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing a New Class of Synthetic Anti-infectives, is pleased to announce its participation alongside Gene
Slide 2: Biotech Investor Lunch
Biotech Investor Lunch May 2022
Slide 3: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre
Slide 4: Management Structure
Management Structure Dr John Prendergast – Chairman James Graham – Chief Executive Officer Michele Dilizia – Chief Scientific Officer BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) BCom (Entrepreneurship), GAICD BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US based, current Chairman a
Slide 5: A Versatile Technology Platform
A Versatile Technology Platform Biotech company developing Anti-infectives targeting both bacterial and viral indications Strong IP and own manufacturing capability Versatile delivery platform – oral, intravenous and spray formulations Designed to safely provide treatment without developing resistan
Slide 6: Strong Pipeline
327 435 529 Strong Pipeline Over Various Indications and Upcoming Inflection Points Asset Indications Discovery Preclinical Phase I Phase II Phase III Next data readout Market Size Route of administration Next inflection Market Size Anti-bacterial programs Indication Discovery Preclinical Phase 1 Ph
Slide 7: Sepsis – it’s a big problem!
Sepsis – it’s a big problem! 48.9 million incident One in three patients 11 million sepsis- who die in hospital cases of sepsis related deaths recorded2 have sepsis3 recorded worldwide1 Sepsis is a life-threatening inflammatory response to infection that has spread in the body. Kills more people in
Slide 8: Sepsis Treatment Paradigm
Sepsis Treatment Paradigm Impact of delayed antibiotic treatment on odds ratio for mortality1 Current treatment paradigm relies on: Introducing broad-spectrum antibiotic(s) Running antibiograms Adjusting antibiotics based on antibiogram results Early treatment with the correct antibiotic is key to i
Slide 9: Natural Antibiotics vs Synthetic Anti-Infectives
Natural Antibiotics vs Synthetic Anti-Infectives Pre-formed natural superbugs. All Fungi or Bacteria based ‒ “Penicillin allergy is the most common drug allergy and is reported in up to 15 percent of hospitalized patients” 1 Only as good as what’s found in nature. Natural Antibiotics Has always had
Slide 10: Independent Study Undertaken on R327 MoA
Independent Study Undertaken on R327 MoA1 327 435 529 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 R327 permeabilizes cell membrane and enters the cell R327 interrupts bacterial cellular energetics via ATP Synthesis Stage 3 Stage 4 Cellular division & non-dividing cell functions are
Slide 11: RECCE 327 Multi-Layered Mechanism of Action
327 435 529 RECCE® 327 Multi-Layered Mechanism of Action R327 rapidly & irreversibly R327 affects the assembly of R327 results in the shuts down cellular energetics bacterial cell division complex, decreased formation of the (adenosine triphosphate (ATP) components that require cellular bacterial ce
Slide 12: RECCE 327 Mechanism of Action in Practice
RECCE® 327 Mechanism of Action in Practice Treatment of R327 against E. coli at 1x and 5x MIC leading to disassembly of the FtsZ-GFP rings, supporting initial studies which indicated R327 inactivates cellular bioenergetics and is rapidly and irreversibly bactericidal. R327 E. coli, expressing FtsZ-G
Slide 13: Phase I Human Clinical Trial
327 435 529 Phase I Human Clinical Trial Further Safety and Tolerability Interim Data Expected Q2 2022 Study to assess IV infusion of RECCE® 327 in 80 320x dose amount* 16,000 mg healthy male subjects as a single ascending dose High Dose 160x dose amount* 8,000 mg First cohort 9 subjects dosed Decem
Slide 14: Topical RECCE 327 - Phase I/II
Topical RECCE® 327 - Phase I/II Burn wound infections Phase I/II to assess Topical RECCE® 327 in 20 patients – dosing 3 times/week burn wound infections commenced in Q4 2021. for 2 weeks duration Sponsored by the South Metropolitan Health Service, Department of Health, Government of Western Australi
Slide 15: Topical RECCE 327 – Phase I/II
Topical RECCE® 327 – Phase I/II Patient example from ongoing Burn Wound trial Pre-treatment, significant bacterial infection Patient suffered major burn injury. Multiple bacterial species in and surrounding wound. Growth swabs with organisms including pathogens from the ESKAPE group of bacteria. Pos
Slide 16: Patents
Patents Three families across all major markets Patent Family 1 – Antimicrobial Polymers and Recce’s patent portfolio includes more than 20 issued patents their Compositions and patent applications in the world’s major markets, including Family 1 group relates to the Company’s the United States, Eur
Slide 17: Insourced Manufacturing Capabilities
Insourced Manufacturing Capabilities Wholly owned, automated manufacturing facility in Sydney’s Macquarie Park Raw materials plentiful and cheap – few $/Kg No expensive waste – 99.9% product yield Automated manufacture process taking approximately 1 hour 500 doses per fully automated run Currently p
Slide 18: Recce Pharmaceuticals Ltd – Capital Structure
Recce Pharmaceuticals Ltd – Capital Structure Snapshot Top 20 Shareholders Distribution Tickers ASX:RCE, FSE:R9Q 7% Amount Raised to Date AUD $46 million Market Cap (approx.) AUD $137 million 13 May 2022 27% Cash and deposits AUD $15.90 million 3 April 2022 58% Outstanding shares 174.54 million 8% A
Slide 19: Investment Summary
Investment Summary Proprietary new class of anti-infectives against bacteria and viruses, protected by Composition of Matter Patent. Fast development plans initially targeting: Sepsis, Burn wounds, Helicobacter pylori and COVID-19. Strong pre-clinical data package demonstrating high bactericidal act
Slide 20: Thank you
Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q +61 2 9256 2572 james.graham@recce.com.au recce.com.au
Recce Pharmaceuticals — Investor Presentation (May 2022) on 6ix